Protagen AG Appoints New Board Members
News Oct 05, 2015
Protagen AG, the technology leader in the development of novel molecular diagnostic and companion diagnostic tests for autoimmune diseases, has elected Dr. Dirk Ehlers, CEO of Trumpf Medical in Puchheim, to the company‘s Supervisory Board. Simultaneously, Ulrich Kintzel, Senior Investment Manager of NRW.BANK in Düsseldorf, succeeded Dr. Aristotelis Nastos as representative of NRW.BANK, and Matthias Guth, was appointed by MIG AG in Munich, to follow Michael Motschmann in his board position.
Dr. Ehlers has served in executive positions at Eppendorf, Roche Diagnostics, Evotec, Fresenius Kabi and Olympus Diagnostics and has a proven track record in the Diagnostics Industry, with deep expertise in marketing and commercialization.
According to Dr. Ehlers, “Protagen offers an outstanding technology that addresses the current needs of the autoimmune diagnostics industry, which remains many years behind oncology diagnostics in terms of new molecular content, time to market and therapy support. The Protagen technology is able to deliver novel, validated biomarkers and significantly reduce the time to market. I look forward to supporting the efforts of the company in translating its significant potential into a commercial success story.”
Stefan Müllner, CEO of Protagen, added: “In order to become the leading provider of Dx and CDx for autoimmune therapy, and to foster the potential for strategic collaborations and partnerships, it is imperative that we have meaningful insight into the strategies and processes of the global diagnostic leaders. The profound expertise Dr. Ehlers will bring to this role will provide us with valuable guidance, and will help us to effectively expand our business within the growing and demanding autoimmune Dx field. Together with the expertise of Wolfgang Kintzel, executive manager at AMAXA and CEVEC before joining NRW.BANK, and Matthias Guth, with nearly two decades of experience as investment manager in the biotech industry, Protagen is backed by a Supervisory Board of distinguished industrial experts with synergistic expertise.”
Blood Test To Determine When It Is Safe To Return To Play After A Sports-related ConcussionNews
A high-sensitive blood test can aid concussed hockey players when it might be safe to return to play. In a study published by the journal Neurology, researchers at Sahlgrenska Academy have identified a superior blood-based biomarker for assessing subtle brain injury.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018
16th Annual Conference on Laboratory Medicine and Pathology
Sep 17 - Sep 18, 2018